Imfinzi (durvalumab)

pCPA File Number: 21550
Negotiation Status:
Under consideration for negotiation
Indication(s):
IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CADTH Project Number:
PC0234-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable